Does DKC1 mutation suffice to define the phenotype severity of hoyeraal-hreidarsson syndrome? (2013)
- Authors:
- USP affiliated authors: ROXO JÚNIOR, PÉRSIO - FMRP ; SCRIDELI, CARLOS ALBERTO - FMRP ; TONE, LUIZ GONZAGA - FMRP
- Unidade: FMRP
- DOI: 10.4236/ojbd.2013.31012
- Subjects: MEDULA ÓSSEA; MUTAÇÃO GENÉTICA
- Language: Inglês
- Imprenta:
- Source:
- Título: Open Journal of Blood Diseases
- ISSN: 2164-3180
- Volume/Número/Paginação/Ano: v. 3, n. 1, p. 57-61, 2013
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
VALERA, Elvis Terci et al. Does DKC1 mutation suffice to define the phenotype severity of hoyeraal-hreidarsson syndrome?. Open Journal of Blood Diseases, v. 3, n. 1, p. 57-61, 2013Tradução . . Disponível em: https://doi.org/10.4236/ojbd.2013.31012. Acesso em: 20 fev. 2026. -
APA
Valera, E. T., Brassesco, M. S., Ferraz, S. T., Roxo Junior, P., Santana, B. L., Vulliamy, T., et al. (2013). Does DKC1 mutation suffice to define the phenotype severity of hoyeraal-hreidarsson syndrome? Open Journal of Blood Diseases, 3( 1), 57-61. doi:10.4236/ojbd.2013.31012 -
NLM
Valera ET, Brassesco MS, Ferraz ST, Roxo Junior P, Santana BL, Vulliamy T, Calado RT, Scrideli CA, Tone LG. Does DKC1 mutation suffice to define the phenotype severity of hoyeraal-hreidarsson syndrome? [Internet]. Open Journal of Blood Diseases. 2013 ; 3( 1): 57-61.[citado 2026 fev. 20 ] Available from: https://doi.org/10.4236/ojbd.2013.31012 -
Vancouver
Valera ET, Brassesco MS, Ferraz ST, Roxo Junior P, Santana BL, Vulliamy T, Calado RT, Scrideli CA, Tone LG. Does DKC1 mutation suffice to define the phenotype severity of hoyeraal-hreidarsson syndrome? [Internet]. Open Journal of Blood Diseases. 2013 ; 3( 1): 57-61.[citado 2026 fev. 20 ] Available from: https://doi.org/10.4236/ojbd.2013.31012 - Dificuldades diagnósticas da doença de Kostmann: relato de caso
- Acute lymphoblastic leukemia analyzed by comparative genome hybridization(CGH)
- Silencig of GDF15 gene and response to radiotherapy and the treatment with temozolomide in glioblastoma cell lines
- DHMEQ in pediatric medulloblastoma cell lines
- mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia, low expression levels associated with a higher risk of toxic death
- DHMEQ inhibits in vitro migration and invasion in adult and pediatric glioblastoma cells
- Tetraploidization in Wilms tumor in an infant
- MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL)
- Inibição do crescimento e redução da capacidade clonogênica em linhagens celulares de glioblastomas pediátricos e adultos através do DHMEQ
- Alternative targets for medulloblastoma treatment: polo-like kinase 1
Informações sobre o DOI: 10.4236/ojbd.2013.31012 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
